AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...
AstraZeneca therapy improves breast cancer survival in key trial
Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
GlobalData on MSN3d
AstraZeneca reports positive outcomes from breast cancer combo therapy trial
AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...
BioPharma Dive4d
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
The British drugmaker claimed success in a first-line breast cancer study. Elsewhere, Rezdiffra sales continued to grow and a ...
FierceBiotech4d
AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...
Pharm Exec3d
AstraZeneca’s Camizestrant Shows Survival Improvement for HR-Positive, HER2-Negative Advanced Breast Cancer with Emergent ESR1 Mutations
The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...
BioSpace4d
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...
pharmaphorum4d
Data cues up AZ oral SERD filing in first-line breast cancer
AstraZeneca could become the first company to bring an oral selective oestrogen receptor degrader (SERD) drug to market as a ...
Cure Today1d
Camizestrant Combo Improves Progression Time in HR+/HER2– Breast Cancer
Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in ...
Wall Street Journal4d
AstraZeneca’s Breast Cancer Drug Shows Positive Results In Late-Stage Trial
AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...
Reuters2d
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...